Original Article

You have full text access to this OnlineOpen article

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

  1. Lawrence Serfaty M.D.1,*,
  2. Hugues Aumaître1,
  3. Olivier Chazouillères1,
  4. Anne-Marie Bonnand2,
  5. Olivier Rosmorduc1,
  6. Renée E. Poupon2,
  7. Raoul Poupon1

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510270535

Issue

Hepatology

Hepatology

Volume 27, Issue 5, pages 1435–1440, May 1998

Additional Information

How to Cite

Serfaty, L., Aumaître, H., Chazouillères, O., Bonnand, A.-M., Rosmorduc, O., Poupon, R. E. and Poupon, R. (1998), Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 27: 1435–1440. doi: 10.1002/hep.510270535

Author Information

  1. 1

    Service d'Hépato-gastroentérologie, Hôpital St-Antoine, Assistance Publique-Hôpitaux de Paris, Paris

  2. 2

    INSERM Unit 21, Villejuif, France

*Service d'Hépato-gastroentérologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75571 Paris Cédex 12, France. Fax: 33-1-49-28-21-07

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 13 FEB 1998
  4. Manuscript Received: 13 OCT 1997

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (103K)

REFERENCES

  • 1
    Feray C, Gigou M, Samuel D, Paradis V, David MF, Lemonnier C, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:1137–1143.MEDLINE
  • 2
    Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated Non-A, Non-B hepatitis. N Engl J Med 1992; 327:1906–1911.MEDLINE
  • 3
    Koretz RL, Abey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993; 119:110–115.MEDLINE
  • 4
    Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14:969–74.MEDLINE
    Direct Link:
  • 5
    Hopf U, Küther D, Stemerowicz R, Stemerowicz R, Lobeck H, Lüdtke-Handjery A, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10:69–76.MEDLINE
  • 6
    Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16:273–281.MEDLINE
  • 7
    Tong JM, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463–1466.MEDLINE
  • 8
    Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tomasini M, et al. Hepatocellular carcinoma in italian patients with cirrhosis. N Engl J Med 1991; 325:675–680.MEDLINE
  • 9
    Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18:47–53.MEDLINE
    Direct Link:
  • 10
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797–1801.MEDLINE
  • 11
    Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-years prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21:1029–1034.MEDLINE
  • 12
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. the Collaborative Study Group. Ann Intern Med 1995; 122:161–168.MEDLINE
  • 13
    Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A, et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994; 21:468–473.MEDLINE
  • 14
    Pozzato G, Kaneko S, Morreti M, Saveria Croce L, Franzin F, Unoura M, et al. Different genotypes of hepatitis C virus are associated with different severity of liver disease. J Med Virol 1994; 43:291–296.MEDLINE
    Direct Link:
  • 15
    Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994; 39:234–239.MEDLINE
  • 16
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051–1055.MEDLINE
  • 17
    Mazzela G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141–147.MEDLINE
  • 18
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:1093–1102.MEDLINE
  • 19
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321–1324.MEDLINE
    Direct Link:
  • 20
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431–435.MEDLINE
    Direct Link:
  • 21
    Kaplan EL, Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53:457–481.
  • 22
    Cox DR. Regression models and lifes tables. J R Stat Soc B 1972; 34:248–275.
  • 23
    Serfaty L, Chazouillères O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chrétien Y, et al. Risk factors for liver cirrhosis in patients with chronic HCV infection: results of a case control study. Hepatology 1997; 26:776–779.MEDLINE
    Direct Link:
  • 24
    Pagliaro L, Craxi A, Camma C, Tine F, Di Marco V, Lo Iacono O, et al. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19:820–828.MEDLINE
  • 25
    Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34:1714–1717.MEDLINE
  • 26
    Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21:12–17.MEDLINE
  • 27
    Fattovich G, Giustina G, Degos F, Tremolada F, Diaodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463–472.MEDLINE
  • 28
    Castilla A, Prieto J, Fausto N. Transforming growth factors b 1 and alfa in chronic liver disease. Effects of interferon therapy. N Engl J Med 1991; 324:933–940.MEDLINE
  • 29
    Manabe M, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, et al. Interferon-alfa 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evolution. Hepatology 1993; 18:1344–1349.MEDLINE
    Direct Link:
  • 30
    Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoïd alfa-interferon in chronic hepatitis C. Effect on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17:390–396.MEDLINE
  • 31
    Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploïd fibroblast collagen synthesis by interferon. J Clin Invest 1984; 74:1112–1116.MEDLINE
  • 32
    Mavier P, Préaux AM, Charlotte F, Dhumeaux D, Rosenbaum J. Effects of alpha- and gamma-interferons on the growth and collagen synthesis of human hepatic myofibroblastic Ito cells [Abstract]. Hepatology 1992; 16:185A.
  • 33
    Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma. Hepatology 1993; 18:315–319.MEDLINE
    Direct Link:
  • 34
    Baron S, Tyring SK, Fleischmann WR, Coppenhauer DH, Niesel DW, Klimpel GR. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266:1375–1383.MEDLINE
  • 35
    Sing RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferon alfa and β down-regulate the expression of basic fibroblast growth factor in human carcinoma. Proc Natl Acad Sci U S A 1995; 92:4562–4566.MEDLINE
  • 36
    Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456.MEDLINE
Get PDF (103K)